Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations.
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations.
Rubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility to shape KIFFIK’s clinical strategy.
August 13, 2025 MDL Strategic Communications
PROVIDENCE, RI, August, 12, 2025- KIFFIK Biomedical, Inc. (“Kiffik”), a leader in interstitial fluid (ISF)-based diagnostics, today announced two new appointments to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO) along with Dr. Reginald (Reggie) Swift who will serve as a fractional Chief Scientific Officer (CSO).
“The addition of Rene and Reggie to our already strong leadership team is a game-changer as we embark on our next chapter of growth,” said George Cagna, CEO of KIFFIK Biomedical. “Ensuring our R&D function is meeting the highest scientific standards, coupled with securing operating capital, empowers our team to bring next-generation ISF biomonitoring to partners and patients.”
As CIO, Rene will be responsible for securing capital investments from institutional partners that want to unlock the full potential of interstitial fluid real-time monitoring for a range of cancers and other diseases. Most recently, Rene was Senior Vice President at Locust Walk Partners, LLC where he led multiple high-profile M&A activities on behalf of biopharma clients.
Dr. Reginald Swift is the CEO of Rubix Life Sciences, a leader in aptamer-based precision medicine. As a fractional CSO for Kiffik, Dr. Swift will help shape clinical operations to ensure research and development activities meet the highest scientific standards. Earlier this year, Kiffik and Rubix LS established a strategic partnership to advance next-generation ISF extraction technology.
